Tina M. Albertson - 23 Mar 2022 Form 3 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Chief Medical Officer
Signature
Heather Turner, as Attorney-in-Fact
Issuer symbol
LYEL
Transactions as of
23 Mar 2022
Net transactions value
$0
Form type
3
Filing time
29 Mar 2022, 17:05:31 UTC
Next filing
28 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LYEL Option (right to buy) 23 Mar 2022 Common Stock 500,000 $5.81 Direct F1
holding LYEL Option (right to buy) 23 Mar 2022 Common Stock 400,000 $5.96 Direct F2
holding LYEL Option (right to buy) 23 Mar 2022 Common Stock 600,000 $5.98 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4 of the option shares vested on July 1, 2021, with the remaining option shares to vest in equal monthly installments over the following thirty-six months.
F2 The option shares vest in equal monthly installments over the forty-eight months following December 1, 2020.
F3 12.5% of the option shares shall vest on August 9, 2022, with the remaining option shares to vest in equal monthly installments over the following forty-two months.